Sanara MedTech Inc. Annual Report: A Year in Review

I’ve put together this guide to help you understand how Sanara MedTech Inc. (SMTI) performed this year. My goal is to translate complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Sanara MedTech, based in Plano, Texas, sells high-profit surgical products for wound care and bone fusion. They focus on patients with complex needs, such as those with diabetes or obesity, who face higher risks during surgery. By selling advanced collagen dressings and bone grafts, they help hospitals reduce readmissions and improve patient recovery.

2. A Major Strategic Pivot

The biggest news this year is a major change in strategy. In September 2025, Sanara shut down its "Tissue Health Plus" (THP) service program. After failing to find a partner or buyer, they closed the unit to stop losing money.

This move included a $10.4 million charge to write off the CarePICS acquisition, a digital platform that never became profitable. By exiting this business, Sanara cut overhead costs and can now focus entirely on its growing product line.

3. Financial Performance: The Growth Story

Despite closing a business unit, the core company is growing:

• Revenue is up: They brought in $103.1 million in 2025, a 19% increase from $86.7 million in 2024.
• Where the money comes from: Most revenue comes from "Soft Tissue Repair" products like CellerateRX and FORTIFY ($91.3 million). "Bone Fusion" products like ALLOCYTE and BiFORM brought in $11.8 million.
• The bottom line: The company reported an $18.2 million loss. This was largely due to the one-time costs of shutting down THP and heavy spending on marketing and sales staff.

4. Their "Prepare, Promote, and Protect" Strategy

Sanara organizes its products into three simple steps for surgeons:

• Prepare: Using BIASURGE to clean the surgical site and lower infection risks.
• Promote: Using bone-repair products like BiFORM to help the body rebuild bone structure.
• Protect: Using CellerateRX Surgical to cover wounds and support natural healing.

5. The "Reality Check": Risks to Your Investment

Investing in Sanara comes with significant risks:

• Debt Pressure: Sanara carries $55 million in debt. While they extended their payment deadlines in 2025, the interest costs make it difficult to turn a profit.
• "All-In" Risk: Sanara is now a "pure-play" product company. If growth slows or hospitals switch to cheaper alternatives, they have no other business lines to fall back on.
• Competition: Their flagship product, CellerateRX, relies on trade secrets rather than long-term patents. If a competitor creates a cheaper version, Sanara’s profit margins could shrink.
• Stock Control: Insiders own 42% of the company. Retail investors have almost no say in board decisions.
• No Dividends: The company does not pay dividends and likely won't soon, as they prioritize paying off debt and funding new research.

6. Future Outlook

Sanara is now focused entirely on surgical products. They are expanding their sales team to reach more orthopedic and podiatric surgeons. They are also adding new products, like the OsStic bone-filler, to increase sales per procedure. Success now depends on maintaining high growth to pay off debt and eventually reach positive cash flow.

Final Thought for Investors: Sanara is currently a "growth-at-all-costs" company. They have successfully scaled their core product revenue, but they are still burning cash to pay down debt and fund their sales expansion. If you are looking for a stable, dividend-paying stock, this likely isn't it. However, if you believe their surgical product strategy will eventually outpace their debt obligations, it is a company to watch as they transition toward profitability.